Tharimmune Announces Topline Data With TH104, Its Lead Candidate For Moderate-To-Severe Pruritus In Chronic Liver Disease Patients
Portfolio Pulse from Benzinga Newsdesk
Tharimmune reported positive Phase 1 results for TH104, its treatment for pruritus in chronic liver disease patients, showing a 33.3% reduction in itching intensity. The drug was well tolerated, with no unexpected adverse events. The company is funded into early 2025 and anticipates US PK data and Phase 2a results in 2024.
December 11, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune's positive Phase 1 trial results for TH104 could boost investor confidence, with a significant reduction in pruritus symptoms and good tolerability. The company's financial runway into early 2025 and upcoming trials may further support the stock.
Positive clinical trial results typically lead to increased investor confidence and can drive up a biotech company's stock price. The news of TH104's efficacy and safety, along with the company's financial stability, is likely to be viewed favorably by the market. However, as the drug is still in early stages of development, there remains some uncertainty until further trial results are released.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100